Articles related to CARDIORENAL OUTCOMES

ACC Releases 2026 Expert Consensus Decision Pathway on HFpEF

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

Cardiology August 11th 2026

Tags: CARDIORENAL OUTCOMES GLP-1 RECEPTOR AGONISTS GUIDELINES/RECOMMENDATIONS HEART FAILURE (HF) OBESITY/WEIGHT MANAGEMENT SGLT2 INHIBITORS TYPE 2 DIABETES

Medical News Today (MNT)

Could a Common Blood Pressure Drug Worsen Kidney Disease in Type 2 Diabetes?

A 31,000-patient observational study found that dihydropyridine calcium-channel blockers were associated with a 33% higher risk of major adverse kidney events in type 2 diabetes patients already on RASi and SGLT2i therapy.

Cardiology June 22nd 2026

Tags: ANTIHYPERTENSIVES CARDIORENAL OUTCOMES DIABETIC KIDNEY DISEASE HYPERTENSION/BLOOD PRESSURE KIDNEY DISEASE TYPE 2 DIABETES

MDSpire News

Tirzepatide Linked to Lower Cardiorenal Events

A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.

Cardiology May 5th 2026

Tags: CARDIORENAL OUTCOMES CHRONIC DISEASE MANAGEMENT CLINICAL STUDY DRUG SAFETY & INTERACTIONS EVIDENCE REVIEW INCRETIN THERAPY PHARMACOTHERAPY RISK STRATIFICATION

Trending Topics:

Articles related to CARDIORENAL OUTCOMES

ACC Releases 2026 Expert Consensus Decision Pathway on HFpEF

Could a Common Blood Pressure Drug Worsen Kidney Disease in Type 2 Diabetes?

Tirzepatide Linked to Lower Cardiorenal Events

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form